Published in PLoS One on April 23, 2014
The Clinical Effectiveness of Pneumococcal Conjugate Vaccines. Dtsch Arztebl Int (2016) 1.49
A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. Hum Vaccin Immunother (2015) 0.91
Pneumococcal Vaccination Guidance for Post-Acute and Long-Term Care Settings: Recommendations From AMDA's Infection Advisory Committee. J Am Med Dir Assoc (2017) 0.75
Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial. Hum Vaccin Immunother (2015) 0.75
The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease. Clin Kidney J (2015) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis (2010) 8.37
Serotype replacement in disease after pneumococcal vaccination. Lancet (2011) 7.14
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis (2011) 5.31
Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality. J Am Geriatr Soc (2005) 4.48
Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ (2009) 4.38
Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev (2008) 3.13
Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc (2006) 2.91
Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev (2013) 2.49
Biology of immune responses to vaccines in elderly persons. Clin Infect Dis (2008) 2.32
The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis (2009) 2.02
The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis (2005) 1.64
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine (2011) 1.61
Vaccination in the elderly: an immunological perspective. Trends Immunol (2009) 1.60
Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med (2008) 1.57
Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis (2008) 1.55
Immunological responses to pneumococcal vaccine in frail older people. Vaccine (2008) 1.36
Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell Q Rep (2008) 1.30
Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines (2011) 1.29
The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis (2011) 1.14
Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis (2008) 1.14
A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides. Immunol Invest (2001) 1.13
The challenges of clinical trials in the exclusion zone: the case of the frail elderly. Australas J Ageing (2008) 1.06
Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Clin Infect Dis (2009) 1.05
A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis (2011) 1.04
The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine (2010) 1.01
Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr Int (2008) 0.90
Pneumococcal disease in South Australia: vaccine success but no time for complacency. Vaccine (2012) 0.89
Invasive pneumococcal disease in non-Indigenous people in north Queensland, 2001-2009. Med J Aust (2010) 0.89
Epidemiology of invasive pneumococcal disease in urban New South Wales, 1997-1999. Med J Aust (2000) 0.88
Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis (2012) 0.86
Pneumococcal conjugate vaccine, polysaccharide vaccine, or both for adults? We're not there yet. Clin Infect Dis (2009) 0.83
Activity Index - a complementary ADL scale to the Barthel Index in the acute stage in patients with severe stroke. Cerebrovasc Dis (2006) 0.82
Predictors of pneumococcal vaccination uptake in hospitalized patients aged 65 years and over shortly following the commencement of a publicly funded national pneumococcal vaccination program in Australia. Hum Vaccin (2007) 0.77